- Home
- ALDX
as 07-26-2024 4:00pm EST
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 229.9M | IPO Year: | 2014 |
| Target Price: | $9.33 | AVG Volume (30 days): | 359.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.42 - $8.38 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 55.91% |
Stock Insider Trading Activity of Aldeyra Therapeutics Inc. (ALDX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | ALDX | 10% Owner | Apr 4 '24 | Buy | $4.67 | 140,281 | $655,112.27 | 9,238,139 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | ALDX | 10% Owner | Apr 4 '24 | Buy | $4.74 | 37,712 | $178,754.88 | 9,275,851 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | ALDX | 10% Owner | Apr 1 '24 | Buy | $4.09 | 309,847 | $1,267,274.23 | 9,097,858 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | ALDX | 10% Owner | Apr 1 '24 | Buy | $3.44 | 186,051 | $640,015.44 | 8,788,011 | SEC Form 4 |
| PERCEPTIVE ADVISORS LLC | ALDX | 10% Owner | Apr 1 '24 | Buy | $3.25 | 8,374 | $27,215.50 | 8,601,960 | SEC Form 4 |
| Machatha Stephen | ALDX | Chief Development Officer | Mar 12 '24 | Sell | $3.16 | 11,537 | $36,503.07 | 252,812 | SEC Form 4 |
| Greenberg Bruce | ALDX | See Remarks | Mar 11 '24 | Sell | $3.41 | 13,201 | $44,967.89 | 130,154 | SEC Form 4 |
| Greenberg Bruce | ALDX | See Remarks | Mar 9 '24 | Sell | $3.41 | 13,201 | $44,967.89 | 120,699 | SEC Form 4 |
| Machatha Stephen | ALDX | Chief Development Officer | Mar 9 '24 | Sell | $3.41 | 18,231 | $62,102.08 | 255,032 | SEC Form 4 |
| Machatha Stephen | ALDX | Chief Development Officer | Mar 9 '24 | Sell | $3.16 | 11,537 | $36,503.07 | 243,495 | SEC Form 4 |
| Brady Todd C | ALDX | President and CEO | Mar 9 '24 | Sell | $3.27 | 97,914 | $320,521.48 | 1,556,622 | SEC Form 4 |
| Brady Todd C | ALDX | President and CEO | Mar 9 '24 | Sell | $3.05 | 85,324 | $260,238.20 | 1,471,298 | SEC Form 4 |
Latest Aldeyra Therapeutics Inc. News
ALDX Breaking Stock News: Dive into ALDX Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
Clinical Trials Arena
a month ago
Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial
Business Wire
a month ago
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
Business Wire
a month ago
Aldeyra Therapeutics to Host Investor Roundtable Q&A
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Business Wire
2 months ago
Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
AFP
2 months ago
New Zealand scraps plan to tax livestock burps, farts
Compare ALDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALDX Aldeyra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.